Opinion

Video

How Often Do Patients with ASCVD Achieve Target LDL-C?

A panel of clinical pharmacists introduce themselves and discuss how LDL cholesterol target achievement compares with guideline goals for patients with ASCVD who are treated with maximally tolerated statin monotherapy.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
Atrial fibrillation (AF) -- Image credit: ibreakstock | stock.adobe.com
July 14th 2025

FDA Approves Expanded Labeling of Farapulse PFA System for Persistent Atrial Fibrillation

Gillian McGovern, Associate Editor
An Overview of Intravenous Iron in Heart Failure and the FAIR-HF2 Trial
July 1st 2025

An Overview of Intravenous Iron in Heart Failure and the FAIR-HF2 Trial

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
Highlights From NLA 2025: Early LDL-C Reduction and Emerging Therapies
July 9th 2025

Highlights From NLA 2025: Early LDL-C Reduction and Emerging Therapies

Jennifer D. Goldman, PharmD, CDE, BC-ADM, FCCP Alana Hippensteele, Lead Editor
Concierge Pharmacy's Role in Cardio-Kidney-Metabolic Health Care
June 17th 2025

Concierge Pharmacy's Role in Cardio-Kidney-Metabolic Health Care

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
Medical heart cardiology concept | Image Credit: Peera | stock.adobe.com
Published: July 7th 2025 | Updated: July 7th 2025

Integrity Concerns in Ticagrelor Trials Challenge Clinical Confidence

Danielle Valletti, Assistant Editor
Cardiomyopathy (ATTR-CM) -- Image credit: Dzmitry | stock.adobe.com
July 1st 2025

Pharmacists Have a Crucial Role Helping Patients With ATTR-CM Navigate Treatment With Tafamidis

Gillian McGovern, Associate Editor Jennifer Goldman, PharmD, CDES, BC-ADM, FCCP